Literature DB >> 18728248

Telomerase activity of HIV-1-specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors.

Mathias Lichterfeld1, Danlei Mou, Thai Duong Hong Cung, Katie L Williams, Michael T Waring, Jinghe Huang, Florencia Pereyra, Alicja Trocha, Gordon J Freeman, Eric S Rosenberg, Bruce D Walker, Xu G Yu.   

Abstract

Exhaustion of virus-specific T cells may play an important role in the pathophysiology of chronic viral infections. Here, we analyzed telomere length and telomerase activity in HIV-1-specific CD8+ T cells from progressors or controllers to determine underlying molecular pathways of T-cell exhaustion and senescence. Telomere lengths of HIV-1-specific CD8+ T cells from progressors were significantly shorter compared with autologous cytomegalovirus (CMV)/Epstein-Barr virus (EBV)-specific CD8+ T cells or bulk CD8+ T cells, while telomere lengths from controllers significantly exceeded those of autologous bulk CD8+ T cells and reached a similar level as HIV-1-specific CD8+ T cells collected during primary HIV-1 infection. Telomere length stabilization in controllers corresponded to high levels of constitutive telomerase activity, which was associated with preservation of cytotoxic and proliferative properties. Conversely, limited constitutive telomerase activity was observed in HIV-1-specific CD8+ T cells from progressors, although an increase in both telomere length and telomerase activity was achieved in antigenic-peptide-stimulated cells from progressors after blocking the PD-1/PD ligand 1 (PD-L1) pathway. Collectively, these data suggest a causal role of telomere shortening for the functional deficiencies of HIV-1-specific CD8+ T cells in chronic progressive infection, while high constitutive telomerase activities appears to contribute to maintenance of polyfunctional HIV-1-specific CD8+ T cells from HIV-1 controllers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18728248      PMCID: PMC2572795          DOI: 10.1182/blood-2008-01-135442

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Induction of telomerase activity and maintenance of telomere length in virus-specific effector and memory CD8+ T cells.

Authors:  Karen S Hathcock; Susan M Kaech; Rafi Ahmed; Richard J Hodes
Journal:  J Immunol       Date:  2003-01-01       Impact factor: 5.422

2.  Telomerase levels control the lifespan of human T lymphocytes.

Authors:  Alexander Roth; Hans Yssel; Jerome Pene; Elizabeth A Chavez; Mike Schertzer; Peter M Lansdorp; Hergen Spits; Rosalie M Luiten
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

Review 3.  Immune activation and inflammation in HIV-1 infection: causes and consequences.

Authors:  V Appay; D Sauce
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

4.  Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions.

Authors:  Rita B Effros; Courtney V Fletcher; Kelly Gebo; Jeffrey B Halter; William R Hazzard; Frances McFarland Horne; Robin E Huebner; Edward N Janoff; Amy C Justice; Daniel Kuritzkes; Susan G Nayfield; Susan F Plaeger; Kenneth E Schmader; John R Ashworth; Christine Campanelli; Charles P Clayton; Beth Rada; Nancy F Woolard; Kevin P High
Journal:  Clin Infect Dis       Date:  2008-08-15       Impact factor: 9.079

5.  The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences.

Authors:  Stephen A Migueles; Alisha C Laborico; Hiromi Imamichi; W Lesley Shupert; Cassandra Royce; Mary McLaughlin; Linda Ehler; Julia Metcalf; Shuying Liu; Claire W Hallahan; Mark Connors
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

6.  Epitope escape mutation and decay of human immunodeficiency virus type 1-specific CTL responses.

Authors:  Beth D Jamieson; Otto O Yang; Lance Hultin; Mary Ann Hausner; Patricia Hultin; Jose Matud; Kevin Kunstman; Scott Killian; John Altman; Kristina Kommander; Bette Korber; Janis Giorgi; Steven Wolinsky
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

7.  SYBR Green real-time telomeric repeat amplification protocol for the rapid quantification of telomerase activity.

Authors:  Henning Wege; Michael S Chui; Hai T Le; Julie M Tran; Mark A Zern
Journal:  Nucleic Acids Res       Date:  2003-01-15       Impact factor: 16.971

8.  The loss of telomerase activity in highly differentiated CD8+CD28-CD27- T cells is associated with decreased Akt (Ser473) phosphorylation.

Authors:  Fiona J Plunkett; Ornella Franzese; Helene M Finney; Jean M Fletcher; Lavina L Belaramani; Mike Salmon; Inderjeet Dokal; David Webster; Alastair D G Lawson; Arne N Akbar
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

9.  Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection.

Authors:  Haina Shin; Shawn D Blackburn; Joseph N Blattman; E John Wherry
Journal:  J Exp Med       Date:  2007-04-09       Impact factor: 14.307

10.  Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover.

Authors:  Jorge R Almeida; David A Price; Laura Papagno; Zaïna Aït Arkoub; Delphine Sauce; Ethan Bornstein; Tedi E Asher; Assia Samri; Aurélie Schnuriger; Ioannis Theodorou; Dominique Costagliola; Christine Rouzioux; Henri Agut; Anne-Geneviève Marcelin; Daniel Douek; Brigitte Autran; Victor Appay
Journal:  J Exp Med       Date:  2007-09-24       Impact factor: 14.307

View more
  34 in total

Review 1.  A challenge for the future: aging and HIV infection.

Authors:  Tammy M Rickabaugh; Beth D Jamieson
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

Review 2.  Targets of immune regeneration in rheumatoid arthritis.

Authors:  Philipp J Hohensinner; Jörg J Goronzy; Cornelia M Weyand
Journal:  Mayo Clin Proc       Date:  2014-04       Impact factor: 7.616

3.  Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity.

Authors:  Jorge R Almeida; Delphine Sauce; David A Price; Laura Papagno; So Youn Shin; Arnaud Moris; Martin Larsen; Gianfranco Pancino; Daniel C Douek; Brigitte Autran; Asier Sáez-Cirión; Victor Appay
Journal:  Blood       Date:  2009-04-23       Impact factor: 22.113

4.  Are senescence and exhaustion intertwined or unrelated processes that compromise immunity?

Authors:  Arne N Akbar; Sian M Henson
Journal:  Nat Rev Immunol       Date:  2011-04       Impact factor: 53.106

Review 5.  T cell exhaustion.

Authors:  E John Wherry
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

6.  Strength of PD-1 signaling differentially affects T-cell effector functions.

Authors:  Fang Wei; Shi Zhong; Zhengyu Ma; Hong Kong; Andrew Medvec; Rafi Ahmed; Gordon J Freeman; Michelle Krogsgaard; James L Riley
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-22       Impact factor: 11.205

Review 7.  Stress and immunosenescence: The role of telomerase.

Authors:  Karin de Punder; Christine Heim; Pathik D Wadhwa; Sonja Entringer
Journal:  Psychoneuroendocrinology       Date:  2018-10-23       Impact factor: 4.905

Review 8.  T cell replicative senescence in human aging.

Authors:  Jennifer P Chou; Rita B Effros
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

9.  Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes.

Authors:  Steven Russell Fauce; Beth D Jamieson; Allison C Chin; Ronald T Mitsuyasu; Stan T Parish; Hwee L Ng; Christina M Ramirez Kitchen; Otto O Yang; Calvin B Harley; Rita B Effros
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

10.  HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study.

Authors:  Gregory D Kirk; Shruti H Mehta; Jacquie Astemborski; Noya Galai; Jonathan Washington; Yvonne Higgins; Ashwin Balagopal; David L Thomas
Journal:  Ann Intern Med       Date:  2013-05-07       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.